Were you or are you an early-stage breast cancer patient who lives in and accesses health care in Ontario? If so, the Canadian Cancer Survivor Network would like your input to help us with our Patient Evidence Submission to Health Quality Ontario (HQO) on Gene Expression Profiling (GEP) tests.
CCSN is preparing a patient evidence submission on Gene Expression Profiling testing to HQO, which is currently conducting a health technology assessment for early invasive breast cancer. Your opinions on Gene Expression Profiling as it relates to your experience with breast cancer will provide the expert committee at HQO with valuable perspective as they prepare their final funding recommendation to make these tests available in Ontario. You do not need to have any experience with Gene Expression Profiling to take the survey.
Gene Expression Profiling tests analyze a sample of the breast cancer tissue to identify the presence or absence of certain genes (eight disease relevant genes and four control genes) in the cancer cell in early stage breast cancers (Stage I and II). This information may help physicians determine the likelihood that the cancer will return after surgery and can help guide decisions about whether a patient may benefit from chemotherapy.
If you would like to be part of the conversation around this technology and whether it should be made easily accessible to Ontario breast cancer patients, please take 10 minutes to fill out the survey: https://connect.impetusdigital.com/gep-ccsn
The completion deadline is Monday, Oct. 14, 2019.
Please note: Patient privacy and confidentiality will be maintained at all times.